Peroxisome proliferator-activated receptors at the crossroads of obesity, diabetes, and cardiovascular disease

被引:27
作者
Gilde, Andries J.
Fruchart, Jean-Charles
Staels, Bart
机构
[1] Inst Pasteur, INSERM, U545, F-59019 Lille, France
[2] Inst Pasteur, Dept Atherosclerosis, F-59019 Lille, France
[3] Univ Lille 2, F-59800 Lille, France
关键词
D O I
10.1016/j.jacc.2006.04.097
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Since their discovery in the early 1990s, the members of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors have been recognized as therapeutic targets against dyslipidemia and diabetes. Recent studies also identified anti-inflammatory actions of PPARs in cells constituting the atherosclerotic lesion. Delineation of this activity extended the therapeutic potential of PPAR activators beyond their original design as metabolic controllers. The PPAR family consists of 3 PPAR isoforms: alpha, beta/delta, and gamma, which exert different and sometimes overlapping effects on whole-body physiology in particular on lipid and glucose metabolism. This review summarizes the current knowledge on the role of PPARs in cardiovascular disease, the metabolic syndrome, atherosclerosis, and cardiac function.
引用
收藏
页码:A24 / A32
页数:9
相关论文
共 125 条
[41]   PPARα inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a [J].
Gizard, F ;
Amant, C ;
Barbier, O ;
Bellosta, S ;
Robillard, R ;
Percevault, F ;
Sevestre, H ;
Krimpenfort, P ;
Corsini, A ;
Rochette, J ;
Glineur, C ;
Fruchart, JC ;
Torpier, G ;
Staels, B .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (11) :3228-3238
[42]   A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia [J].
Goldberg, RB ;
Kendall, DM ;
Deeg, MA ;
Buse, JB ;
Zagar, AJ ;
Pinaire, JA ;
Tan, MH ;
Khan, MA ;
Perez, AT ;
Jacober, SJ .
DIABETES CARE, 2005, 28 (07) :1547-1554
[43]   Activation of peroxisome proliferator-activated receptor-α and -γ in auricular tissue from heart failure patients [J].
Gómez-Garre, D ;
Herraíz, M ;
González-Rubio, ML ;
Bernal, R ;
Aragoncillo, P ;
Carbonell, A ;
Rufilanchas, JJ ;
Fernández-Cruz, A .
EUROPEAN JOURNAL OF HEART FAILURE, 2006, 8 (02) :154-161
[44]   Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity [J].
Guerre-Millo, M ;
Gervois, P ;
Raspé, E ;
Madsen, L ;
Poulain, P ;
Derudas, B ;
Herbert, JM ;
Winegar, DA ;
Willson, TM ;
Fruchart, JC ;
Berge, RK ;
Staels, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (22) :16638-16642
[45]   Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth [J].
Gupta, RA ;
Wang, DZ ;
Katkuri, S ;
Wang, HB ;
Dey, SK ;
DuBois, RN .
NATURE MEDICINE, 2004, 10 (03) :245-247
[46]   Missense variants in the human peroxisome proliferator-activated receptor-γ2 gene in lean and obese subjects [J].
Hamann, A ;
Münzberg, H ;
Buttron, P ;
Büsing, B ;
Hinney, A ;
Mayer, H ;
Siegfried, W ;
Hebebrand, J ;
Greten, H .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1999, 141 (01) :90-92
[47]   Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis [J].
Harman, FS ;
Nicol, CJ ;
Marin, HE ;
Ward, JM ;
Gonzalez, FJ ;
Peters, JM .
NATURE MEDICINE, 2004, 10 (05) :481-483
[48]   Obesity [J].
Haslam, DW ;
James, WPT .
LANCET, 2005, 366 (9492) :1197-1209
[49]   Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle [J].
He, WM ;
Barak, Y ;
Hevener, A ;
Olson, P ;
Liao, D ;
Le, J ;
Nelson, M ;
Ong, E ;
Olefsky, JM ;
Evans, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (26) :15712-15717
[50]   Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo -: A study using the novel PPARα/γ agonist tesaglitazar [J].
Hegarty, BD ;
Furler, SM ;
Oakes, ND ;
Kraegen, EW ;
Cooney, GJ .
ENDOCRINOLOGY, 2004, 145 (07) :3158-3164